Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3850430 | American Journal of Kidney Diseases | 2009 | 9 Pages |
Abstract
Although the studies are limited by small numbers of subjects, short durations of follow-up, and variable quality, these results suggest that compared with standard care, ascorbic acid use may result in an increase in hemoglobin concentration and transferrin saturation and decrease in rHuEPO requirements. Longer term studies are required to confirm these results, provide information about adverse events, and determine whether these changes translate into improved patient outcomes and cost-effectiveness.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Vinay MD, Penelope MD, Matthew T. MD, Marcello MD, SM, Braden J. MD, MSc, Michael MD, Brenda R. MD, PhD, Alberta Kidney Disease Network Alberta Kidney Disease Network,